Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Tonix Pharmaceuticals Holding / Equity Bottom-Up

<ul><li>On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the FDA will not require an Advisory Committee meeting regarding the New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia.</li><li>An Advisory Committee meeting is scheduled when the FDA needs expert input regarding some or all aspects of the NDA.</li><li>The fact that the FDA will not require Advisory Committee meeting is a indicative that the FDA has sufficient information to render a decision on TNX-102 SL.</li></ul>

On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the FDA will not require an Advisory Committee meeting regarding the New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia.An Advisory Committee meeting is scheduled when the FDA needs expert input regarding some or all aspects of the NDA.The fact that the FDA will not require Advisory Committee meeting is a indicative that the FDA has sufficient information to render a decision on TNX-102 SL.

TNXP: No AdCom Required for TNX-102 SL NDA 